Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials
about
Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trialsDose finding with longitudinal data: simpler models, richer outcomes.Challenges in the evaluation, consent, ethics and history of early clinical trials - Implications of the Tuskegee 'trial' for safer and more ethical clinical trialsA robust Bayesian dose-finding design for phase I/II clinical trials.Adaptive designs for dual-agent phase I dose-escalation studies.Adaptive phase I/II clinical trials for drug combination assessment in oncology using the outcomes of each cycle.A Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities.Simple benchmark for complex dose finding studies.Rejoinder to comments on Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer.Optimizing the concentration and bolus of a drug delivered by continuous infusion.Continual reassessment and related designs in dose-finding studiesAdaptive randomization to improve utility-based dose-finding with bivariate ordinal outcomes.Optimizing Sedative Dose in Preterm Infants Undergoing Treatment for Respiratory Distress Syndrome.Escalation strategies for combination therapy Phase I trials.Escalation with overdose control for phase I drug-combination trials.Phase I-II clinical trial design: A state-of-the-art paradigm for dose finding.A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups.STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.Application of Bayesian hierarchical models for phase I/II clinical trials in oncology.Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.Parametric Dose Standardization for Optimizing Two-Agent Combinations in a Phase I-II Trial with Ordinal Outcomes.Analyses of drug combinations using missing data shortens trial periods in phase I/II oncology trials.
P2860
Q27023178-1C8C35E5-9F7E-44BB-9A1A-5BE35C84BC31Q30976631-1BAEA417-A753-4404-8A5C-EADCBF195691Q33828105-D5CADAEB-901F-40D9-8F4D-4E722AB6AB39Q37220245-E4A36289-DC44-464B-882B-F501412D05B7Q38090897-D84171D1-F390-46F7-A44E-C447C0E12FF4Q38608632-F0A6B0A0-D6BB-4EC6-A545-3611092BC02FQ39125629-B4222F6D-09BA-455C-9759-50FDB0367EDDQ40819161-207156CA-B487-4D97-9AE2-F636A8ADA6C8Q41903983-9874053A-0D4A-48AF-ACC0-8A382C91C627Q41978664-CDD78650-9FD2-422E-B10A-1C81AD00FE3BQ42172755-01519F39-52C4-4968-9358-46838B8FC75AQ42218729-DC59D77E-EC14-420D-B8EA-4C2E1B1A62E1Q42970340-E7DAFF53-C5E1-4D88-A6DE-7A9AD83BABFEQ43246672-070A02DC-EE3D-4F69-8E14-A94658B4B73DQ45834856-AA46FCEB-177B-47EC-A55D-0C61605FB45CQ47572687-EA1310D5-3BEE-4C44-BF17-51CD927B6464Q48188540-C9F695BF-1DF5-4995-AE90-8BDB760D3DAAQ48275752-A068095E-64A5-4FB9-9961-D768D9AB0FD5Q50542476-BAE76187-08C0-4481-985E-1891919AD7B4Q51001194-C6E88725-A56B-47B1-88A7-6F1481951DB3Q52709604-AA2B6F1B-A027-4F57-A150-A9CE3254AF20Q55306880-00B6FCCB-5B08-4977-B7BA-6E288A8EFEDA
P2860
Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Utility-based optimization of ...... efficacy in phase I/II trials
@ast
Utility-based optimization of ...... efficacy in phase I/II trials
@en
type
label
Utility-based optimization of ...... efficacy in phase I/II trials
@ast
Utility-based optimization of ...... efficacy in phase I/II trials
@en
prefLabel
Utility-based optimization of ...... efficacy in phase I/II trials
@ast
Utility-based optimization of ...... efficacy in phase I/II trials
@en
P2093
P2860
P1433
P1476
Utility-based optimization of ...... efficacy in phase I/II trials
@en
P2093
Andrew Kramar
Hoang Nguyen
Nadine Houede
Peter F Thall
Xavier Paoletti
P2860
P304
P356
10.1111/J.1541-0420.2009.01302.X
P407
P577
2009-08-10T00:00:00Z